Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Companyâs ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.

Employees

373

Sector

Biotechnology & Medical Research

Calendar

2024-11-03 - Q3 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-09-19	59.50 $	-4.51%	1,725,715
24-09-18	62.31 $	+0.61%	1,176,617
24-09-17	61.93 $	-1.56%	1,491,906
24-09-16	62.91 $	+0.98%	1,166,731
24-09-13	62.30 $	+2.91%	942,486

Delayed Quote Nasdaq, September 19, 2024 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

59.50USD

Average target price

61.10USD

Spread / Average Target

+2.69%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-19 pm EDT			5-day change	1st Jan Change
59.50 ^USD	-4.51%		-1.72%	+60.98%

Sep. 19	JPMorgan Downgrades Halozyme Therapeutics to Neutral From Overweight	MT
Sep. 13	FDA Approves Roche Treatment of Multiple Sclerosis Using Halozyme Delivery System	MT

Capitalization	7.54B	P/E ratio 2024 *	17.8x	P/E ratio 2025 *	14.1x
Enterprise value	6.05B	EV / Sales 2024 *	8.7x	EV / Sales 2025 *	7.13x
Free-Float	98.92%	Yield 2024 *	-	Yield 2025 *	-

JPMorgan Downgrades Halozyme Therapeutics to Neutral From Overweight	Sep. 19	MT
FDA Approves Roche Treatment of Multiple Sclerosis Using Halozyme Delivery System	Sep. 13	MT
Roche Gets FDA Approval for Multiple-Sclerosis Treatment	Sep. 13	DJ
Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis	Sep. 13	CI
Halozyme Therapeutics Says FDA Approves Tecentriq Hybreza Cancer Immunotherapy	Sep. 13	MT
Halozyme Therapeutics Insider Sold Shares Worth $1,773,790, According to a Recent SEC Filing	Sep. 13	MT
Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Tecentriq Hybreza? With ENHANZE® for Multiple Types of Cancer	Sep. 12	CI
Halozyme Therapeutics Insider Sold Shares Worth $1,228,020, According to a Recent SEC Filing	Aug. 22	MT
Halozyme Therapeutics Insider Sold Shares Worth $1,689,294, According to a Recent SEC Filing	Aug. 14	MT
Morgan Stanley Raises Price Target on Halozyme Therapeutics to $64 From $59, Keeps Overweight Rating	Aug. 07	MT
Halozyme Therapeutics Q2 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Set	Aug. 06	MT
Halozyme Therapeutics, Inc., Q2 2024 Earnings Call, Aug 06, 2024	Aug. 06
(HALO) HALOZYME THERAPEUTICS Forecasts Fiscal Year 2024 Revenue Range $935M-$1.02B	Aug. 06	MT

JPMorgan Downgrades Halozyme Therapeutics to Neutral From Overweight	Sep. 19	MT
Morgan Stanley Raises Price Target on Halozyme Therapeutics to $64 From $59, Keeps Overweight Rating	Aug. 07	MT
Halozyme Therapeutics Insider Sold Shares Worth $1,100,023, According to a Recent SEC Filing	Jul. 25	MT
Halozyme Therapeutics Insider Sold Shares Worth $269,662, According to a Recent SEC Filing	Jul. 23	MT
Benchmark Adjusts Price Target on Halozyme Therapeutics to $60 From $50, Maintains Buy Rating	Jun. 25	MT

Halozyme Therapeutics, Inc. Stock

Equities

HALO

US40637H1095

Biotechnology & Medical Research

Valuation: Halozyme Therapeutics, Inc.

Chart: Halozyme Therapeutics, Inc.

Latest news: Halozyme Therapeutics, Inc.

Last Transcript: Halozyme Therapeutics, Inc.

Analysts' recommendations: Halozyme Therapeutics, Inc.

Press Releases: Halozyme Therapeutics, Inc.

News in other languages: Halozyme Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Halozyme Therapeutics, Inc.

ETFs: Halozyme Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm	Sep. 17	BU
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis	Sep. 13	PR
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer	Sep. 12	PR
KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer	Sep. 05	AQ
Halozyme to Present at Upcoming Investor Conferences	Aug. 28	PR

Roche: via libera a Tecentriq per via sottocutanea negli USA	Sep. 13
Roche: feu vert à la version sous-cutanée de Tecentriq aux Etats-Unis	Sep. 13
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK: Lyft, Amazon, Fedex, Xpo, Vail Resorts, Unilever...	Jun. 07
ETF: profiteren van de vergrijzing	Nov. 02
ETF: Sacar partido de la longevidad	Nov. 02

1 day	-4.51%
1 week	-1.72%
Current month	-6.81%
1 month	-3.63%
3 months	+18.36%
6 months	+45.80%
Current year	+60.98%

Director	Title	Age	Since
Helen Torley CEO	Chief Executive Officer	61	14-01-05
Nicole LaBrosse DFI	Director of Finance/CFO	41	14-12-31
Mark Snyder CMP	Compliance Officer	57	22-01-02

Manager	Title	Age	Since
Connie Matsui BRD	Director/Board Member	70	06-07-30
Matthew Posard BRD	Director/Board Member	56	13-03-27
Helen Torley CEO	Chief Executive Officer	61	14-01-05

Name	Weight	AuM	1st Jan change	Investor Rating
BLACKROCK FUTURE INNOVATORS ETF - USD	1.48%	5 M€	-1.80%	-
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	0.73%	0 M€	0.00%	-
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	0.55%	0 M€	0.00%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
HALOZYME THERAPEUTICS, INC.	-4.51%	-1.72%	+49.61%	+41.53%	7.54B
VERTEX PHARMACEUTICALS INCORPORATED	+0.79%	-0.16%	+33.39%	+153.80%	123B
REGENERON PHARMACEUTICALS, INC.	+1.00%	-1.23%	+37.46%	+76.44%	124B
ARGENX SE	-0.56%	-1.74%	-1.66%	+73.42%	32.12B
BIONTECH SE	-2.69%	+7.15%	+1.88%	-68.68%	26.75B
BEIGENE, LTD.	+0.66%	+1.18%	-4.92%	-50.74%	21.11B
SUMMIT THERAPEUTICS INC.	-5.70%	-15.51%	+1,131.91%	+263.01%	17.02B
GENMAB A/S	-1.50%	-3.08%	-33.42%	-36.33%	16.74B
WUXI APPTEC CO., LTD.	+1.65%	+2.31%	-49.40%	-73.31%	16.4B
VAXCYTE, INC.	+0.50%	+2.62%	+133.28%	+361.83%	14.49B
Average	-1.04%	-0.27%	+129.81%	+74.10%	39.97B
Weighted average by Cap.	+0.06%	-0.05%	+72.22%	+90.40%

	2024 *	2025 *
Net sales	984M	1.14B
Net income	416M	512M
Net Debt	1.02B	612M